期刊文献+

HPLC法测定安立生坦中R异构体 被引量:3

Determination of R isomer in ambrisentan by HPLC
原文传递
导出
摘要 目的建立HPLC法测定安立生坦中R异构体的方法。方法采用HPLC法,用硅胶键合蛋白质型手性色谱柱ULTRON ES-OVM(150 mm×4.6 mm,5μm);以0.02 mol/L磷酸二氢钾溶液(用磷酸调节p H至4.0)-乙腈(80∶20)为流动相;检测波长220 nm;柱温30℃;体积流量为1.0 m L/min;进样体积20μL。结果安立生坦R异构体在0.501~4.008μg/m L与峰面积线性关系良好(r=0.999 3),平均回收率为98.62%,RSD值为2.82%(n=12)。结论本法操作简便快速,结果准确可靠,可用于安立生坦中R异构体的控制。 Objective To establish an HPLC method for the determination of R optical isomer in ambrisentan. Methods The HPLC was performed on a ULTRON ES-OVM column(250 mm × 4.6 mm, 5 μm); potassium dihydrogen phosphate solution(0.02 mol/L,adjusted to p H 4 with phosphoric acid)- acetonitrile, 80:20 as mobile phase; detection wavelength, 220 nm; column temperature, 30 ℃; flow rate, 1 m L/min; volume of sample, 20 μL. Results A good linear relationship was obtained in the range of 0.501— 4.008 μg/m L(r=0.999 3), and the average recovery was 98.62% with RSD of 2.82%(n = 12). Conclusion The method is convenient, rapid, accurate, and can be used for the determination of R optical isomer in ambrisentan.
出处 《药物评价研究》 CAS 2015年第2期185-188,共4页 Drug Evaluation Research
关键词 安立生坦 R异构体 高效液相色谱 ambrisentan R isomers HPLC
  • 相关文献

参考文献5

二级参考文献83

  • 1唐意红,曾苏.手性药物代谢动力学研究进展[J].分析试验室,2003,22(z1):281-282. 被引量:1
  • 2Lian-Jun Luan.Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects[J].World Journal of Gastroenterology,2005,11(12):1822-1824. 被引量:2
  • 3贾湘曼.手性药物的研究与制备[J].承德医学院学报,2005,22(2):146-148. 被引量:2
  • 4BAKER J G. The selectivity of beta-adrenoceptor antagonists at the human beta-1 ,beta-2 and beta-3 adrenoceptors[J]. Br. J. Pharmacol. , 2005,144 (2) : 317-322.
  • 5CROSSLEY R. Chirality and the biological activity of drugs [ M ]. Boca Raton, Florida : CRC Press, 1995.
  • 6TRIGGLE D J. Stereoselectivity of drug action [ J ]. Drug Discoy. Today, 1997,2(1) : 138-147.
  • 7ROUHI A M. Chiral roundup[J]. Chem. Eng. News ,2002, 80(1) :43-50.
  • 8ISRAEL A, HAVA C, JOHN C. Putting chirality to work : the strategy of chiral of chiral switches [ J ]. Nature Reviews, 2001,1(3) :753-765.
  • 9BLASCHE G, KRAGT H P, FICKENTSCHER K, et al. Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers[J] .Arzneimittelforschung, 1979,29 (7):1 640-1 642.
  • 10REIST M, CARRUPT P A, FRANCOTTE E, et al. Chiral inversion and hydrolysis of thalidomide : mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites[ J]. Chem. Res. Toxicol., 1998,11 (4) : 1 521-1 528.

共引文献33

同被引文献22

  • 1H·里彻尔斯,D·克林吉,W·埃姆伯格,等.新的羧酸衍生物,其制备和应用[P],中国:1160396,1997-09-24.
  • 2E·鲍曼,J·莱恩海默,U·J·沃格尔巴彻,等.3-(杂)芳基羧酸衍生物,其制备和中间体[P].中国:1121711,1996-05-01.
  • 3H·里彻尔斯,D·克林吉,W·埃姆伯格,等.新的羧酸衍生物,其制备和应用[P].中国:1923820,2007-03-07.
  • 4H·里彻尔斯,D·克林吉,W·埃姆伯格,等.新的羧酸衍生物,其制备和应用[P].中国:1513844,2004-07-21.
  • 5Riechers H,Albrecht H P,Amberg W,et al.Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists[J].J Med Chem,1996,39(11):2123-2128.
  • 6H·博纳德,H·理查斯.2-羟基丙酸类消旋物的拆分[P].中国:1325375,2001-12-05.
  • 7刘文芳,傅得兴,胡欣.治疗肺动脉高压新药安贝生坦的药理与临床研究[J].中国新药杂志,2008,17(23):2070-2073. 被引量:6
  • 8马建芳,张帆,林克江,尤启冬.安贝生坦:新型治疗肺动脉高压的选择性内皮素A受体拮抗药[J].中国新药与临床杂志,2009,28(9):641-644. 被引量:2
  • 9周付刚,谷建敏,苏信杰,邢松松,杜玉民.安贝生坦的合成[J].中国医药工业杂志,2010,41(1):1-3. 被引量:11
  • 10彭婕.安贝生坦研究进展[J].医药导报,2010,29(5):640-643. 被引量:5

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部